530 related articles for article (PubMed ID: 23079663)
1. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.
Caro P; Kishan AU; Norberg E; Stanley IA; Chapuy B; Ficarro SB; Polak K; Tondera D; Gounarides J; Yin H; Zhou F; Green MR; Chen L; Monti S; Marto JA; Shipp MA; Danial NN
Cancer Cell; 2012 Oct; 22(4):547-60. PubMed ID: 23079663
[TBL] [Abstract][Full Text] [Related]
2. Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets.
Norberg E; Lako A; Chen PH; Stanley IA; Zhou F; Ficarro SB; Chapuy B; Chen L; Rodig S; Shin D; Choi DW; Lee S; Shipp MA; Marto JA; Danial NN
Cell Death Differ; 2017 Feb; 24(2):251-262. PubMed ID: 27768122
[TBL] [Abstract][Full Text] [Related]
3. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
[TBL] [Abstract][Full Text] [Related]
5. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
[TBL] [Abstract][Full Text] [Related]
6. FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.
Sewastianik T; Szydlowski M; Jablonska E; Bialopiotrowicz E; Kiliszek P; Gorniak P; Polak A; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Kaminski TS; Markowicz S; Nowak E; Grygorowicz MA; Warzocha K; Juszczynski P
Oncogene; 2016 Nov; 35(46):5989-6000. PubMed ID: 27132507
[TBL] [Abstract][Full Text] [Related]
7. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
8. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
[TBL] [Abstract][Full Text] [Related]
9. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
10. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
[TBL] [Abstract][Full Text] [Related]
12. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
Mensah AA; Spriano F; Sartori G; Priebe V; Cascione L; Gaudio E; Tarantelli C; Civanelli E; Aresu L; Rinaldi A; Damia G; Lovati E; Zucca E; Stathis A; Pietra C; Bertoni F
Blood Adv; 2021 May; 5(10):2467-2480. PubMed ID: 33999145
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
Monti S; Savage KJ; Kutok JL; Feuerhake F; Kurtin P; Mihm M; Wu B; Pasqualucci L; Neuberg D; Aguiar RC; Dal Cin P; Ladd C; Pinkus GS; Salles G; Harris NL; Dalla-Favera R; Habermann TM; Aster JC; Golub TR; Shipp MA
Blood; 2005 Mar; 105(5):1851-61. PubMed ID: 15550490
[TBL] [Abstract][Full Text] [Related]
14. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.
Young RM; Wu T; Schmitz R; Dawood M; Xiao W; Phelan JD; Xu W; Menard L; Meffre E; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Staudt LM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13447-54. PubMed ID: 26483459
[TBL] [Abstract][Full Text] [Related]
15. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
16. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.
Rink JS; Yang S; Cen O; Taxter T; McMahon KM; Misener S; Behdad A; Longnecker R; Gordon LI; Thaxton CS
Mol Pharm; 2017 Nov; 14(11):4042-4051. PubMed ID: 28933554
[TBL] [Abstract][Full Text] [Related]
17. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
Dunleavy K; Erdmann T; Lenz G
Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872
[TBL] [Abstract][Full Text] [Related]
18. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
[TBL] [Abstract][Full Text] [Related]
20. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
